Background: Elevated hsCRP (high‐sensitivity C‐reactive protein) level is associated with worse prognosis among patients hospitalized for heart failure. However, the prognostic value of the long‐term cumulative hsCRP remains unknown. Methods and Results: We consecutively enrolled patients hospitalized for heart failure and collected their hsCRP data at admission and 1 and 12 months after discharge. Long‐term cumulative hsCRP was evaluated using 2 approaches, cumulative hsCRP level quartiles and cumulative times of high hsCRP levels. Patients were classified into 4 groups by cumulative hsCRP level quartiles and cumulative times of high hsCRP levels (0‐ to 3‐times: number of times that hsCRP levels were higher than cutoff values at admission or 1 or 12 months), respectively. Multivariable Cox models were used to assess the association of mortality with cumulative hsCRP. A total of 1281 patients were included; the median age was 64 (interquartile range, 54–73) years, and 35.4% were women. Over a 4.8‐year (interquartile range, 4.2–5.1) follow‐up, 374 (29.2%) patients died. Elevated long‐term cumulative hsCRP level was related to higher mortality. Specifically, taking the quartile 1 as the reference, the hazard ratios (HRs) were 1.29 (95% CI, 0.92–1.81) for quartile 2, 1.62 (95% CI, 1.16–2.25) for quartile 3, and 2.38 (95% CI, 1.75–3.23) for quartile 4. Similarly, compared with the patients with 0‐times (hsCRP level lower than the cutoff values in all 3 time points) of high hsCRP level, the HRs were 1.36 for 1‐time (hsCRP level higher than the cutoff value in one of the 3 time points) (95% CI, 0.92–2.01), 1.95 for 2‐times (hsCRP levels higher than the cutoff values in 2 of the 3 time points) (95% CI, 1.34–2.82), and 2.80 for 3‐times (hsCRP levels higher than the cutoff values in the 3 time points) (95% CI, 1.97–4.00). Conclusions: Increasing long‐term cumulative hsCRP level was associated with worse outcomes in patients hospitalized for acute heart failure. Repeated hsCRP measurements could assist physicians in identifying patients with a high risk of death. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT 02878811.
25 September 2025 in The Lancet Regional Health - Western Pacific
Current international guidelines on dyslipidemia were formulated based on the research performed mostly in White populations. However, whether the association of triglycerides (TGs) with cardiovascular disease (CVD) differs between Chinese and White populations is unknown. 3,789,025 participants from the China Health Evaluation And risk Reduction through nationwide Teamwork (ChinaHEART) were evaluated for the association between TGs and all-cause and CVD mortality with Cox regression models. The findings were tested for sex-specific differences and contrasted with another comparison cohort of 434,919 UK Biobank participants. 92,888 Chinese adults died during a median follow-up of 4.6 years. All-cause and CVD mortality initially increased with TG elevation abruptly and plateaued in Chinese men, while U-shaped associations were seen in Chinese women. In contrast, CVD risk increased incrementally with TGs in White people. Hazard ratios (95% confidence intervals) were 1.02 (0.97–1.07), 1.05 (1.00–1.11), 1.07 (1.02–1.22), and 1.19 (1.13–1.24) from TG quintile 2 to 5 for White men, and 1.14 (1.08–1.21), 1.17 (1.11–1.24), 1.26 (1.18–1.33), and 1.41 (1.33–1.50) for White women, respectively. The association with CVD mortality was stronger in Chinese men who were lean, normotensive, and smoking but in Chinese women with diabetes. The association of TGs with CVD was different for the White and the Chinese populations. That mortality risk elevated in conventionally low-to-moderate TG range implicates that more aggressive intervention may be merited for Chinese and other East Asian populations. The National High Level Hospital Clinical Research Funding (2023-GSP-ZD-2, 2023-GSP-RC-01), the 10.13039/501100005045 Ministry of Finance , and the 10.13039/501100018684 National Health Commission of China.
15 July 2025 in Journal of the National Cancer Center
Ozone (O3) is recognized as a predominant and increasingly prevalent gaseous pollutant contributing to the Global Burden of Disease. However, its effect on the development of lung cancer has not been adequately acknowledged. Based on Health Evaluation And risk Reduction through nationwide Teamwork (ChinaHEART), a nationwide, population-based cohort study, 2,006,878 participants living in 20,159 communities or villages were passively followed for the incidence of lung cancer through a linkage of data with the National Central Cancer Registry. The average O3 levels over ten years from the year of enrolment in their respective localities were determined based on geographic coordinates. We conducted Cox proportional-hazards regression models to assess the independent hazard ratios (HRs) associated with O3 exposure and the development of lung cancer. During the follow-up of 4.93 million person-years, 4555 new cases of lung cancer were identified. After adjusting for participant characteristics and other environmental factors, we observed a significant positive association between ambient O3 exposure and lung cancer. Compared with participants in the quartile 1 of O3, HRs and 95 % confidence intervals (CI) for the other three quartiles were 1.09 (95 % CI: 1.00-1.17), 1.17 (95 % CI: 1.06-1.29) and 1.42 (95 % CI: 1.26-1.59), respectively. Long-term exposure to ambient O3 is associated with a substantially higher risk of lung cancer. Further studies are needed to explore its pathogenic mechanisms, as well as to evaluate measures for exposure protection or harm mitigation at the individual or population level.
Large-scale genomic initiatives like the UK Biobank have revolutionized our understanding of human disease. These studies typically assume that blood-derived DNA faithfully reflects an individual’s germline genome. However, this assumption is challenged by somatic mutations arising from processes like clonal hematopoiesis. Although standard bioinformatics pipelines employ variant allele frequency (VAF)-based filtering to mitigate such contamination, the efficacy of these approaches requires systematic evaluation. By systematically analyzing germline genome data from large cohorts through applications of mutational signatures, we revealed critical limitations in current filtering methodologies. We found that the mutational spectrum of rare “germline” variants is highly similar to that of somatic mutations. Furthermore, we uncovered that these variants show significant associations with phenotypes such as age, sex, and smoking status, established drivers of somatic mutagenesis. Notably, our multivariable regression models estimated that these somatic artifacts contribute to a substantial excess burden, such as 4.73 mutations per megabase (mut/Mb) in males compared to females, a magnitude exceeding the mutation burden of many cancers. Although the precise absolute size of this contamination may vary depending on specific pathologies and individual environmental exposures, this persistent somatic contamination introduces substantial confounder effects, posing a risk of spurious associations and reverse causality in genetic studies. Our work underscores the urgent reconsideration of two fundamental aspects of genomic research: (1) refinement of variant filtering strategies to better distinguish true germline variants from somatic contaminants, and (2) incorporation of somatic mutagenesis factors as essential covariates in study design. Our findings provide basic guidance for improving the accuracy and interpretability of large-scale genomic studies.